Global Opioids Drug Market Overview:
The opioids drugs is a type of narcotic pain medication that applicable for treatment of severe pain. It is used as an anesthesia, cough suppressant, diarrhea suppressant and to reduce surgical pain. As the numbers of critically ill patients are increasing, demand for orthopedic diseases is also on the rise, leading to growing demand of opioids drugs. There has been significant rise in number of people additives towards opioid overdoses in the U.S. daily with figure stood up to 115 death toll in daily. It also witnessed that 21 to 29 percent of patients who are prescribed opioids for chronic pain misuse them, with 8 to 12 percent developing an opioid use disorder. The major companies are organized awareness programs in Asia-Pacific and Middle East region to prescribe painkillers to help patients overcome opiophobia. According to AMA, the Global Opioids Drug market is expected to see growth rate of 2.1% and may see market size of USD24321.0 Million by 2024.
- Increasing Surgical Procedures and Road Accidents.
- Growing Occurrence of Chronic Pain.
- Rising Demand for opioids drugs in healthcare industries.
- Value Oriented Consumers
- Misuse of Opioids and Consequential Stringent Regulations Hampers the Growth Of Market.
- Rehabilitation Centers Used Methadone and Buprenorphine that Gradually Decreased the Used of Addictive Opioids.
- Rising Demands of Opioids Drugs in Cough Suppressant and Diarrhea Suppressant.
- Growing Palliative Care Facilities Boost the Opioids Drugs Market.
- Legalization of Cannabis as Alternatives of Cannabis may challenge the Market of Opioids Drugs.
Some of the key players profiled in the report are Purdue Pharma L.P (United States), Allergan (Ireland), West-Ward Pharmaceuticals Corporation (United States), Janssen Pharmaceuticals, Inc. (Belgium), Pfizer, Inc. (United States), Egalet Corporation (United States), Sun Pharmaceutical Industries Limited (India), Acura Pharmaceuticals Inc. (United States), Cipher Pharmaceutical Inc. (Canada) and Daiichi Sankyo Inc. (Canada). Additionally, following companies can also be profiled that are part of our coverage like Johnson & Johnson (United States), Lupin Ltd. (India), Teva Pharmaceutical Industries Ltd. (Israel), Actavis Plc (United States), and Egalet (United States). Analyst at AdvanceMarketAnalytics see United States Players to retain maximum share of Global Opioids Drug market by 2024. Considering Market by Receptor Binding, the sub-segment i.e. Strong Agonist will boost the Opioids Drug market.
In April 2019, U.S. Food and Drug Administration launched a public education campaign which is beneficial in providing safe removal of unused opioid pain medicines from homes. It also introduced a “Remove and Risk” Campaign that telecast in television, radio and print public announcements that can used by different organizations, individuals and healthcare providers.
“According to Department of Health and Human Services, Its launched some strategy to combat against opioids addiction, the strategy consist of prevention, treatment and recovery services, data on the epidemic, pain management, targeting of overdose-reversing drugs and research on pain and addiction.”
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Opioids Drug market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Opioids Drug market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Opioids Drugs Manufacturers, Opioids Drugs Traders, End-Use Market Participants of Different Segments of Opioids Drugs, Government and Research Organizations, R&D Institutions and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.